Navigation Links
Azithromycin Doesn't Always Help Lungs in Cystic Fibrosis Patients
Date:5/4/2010

Antibiotic helped some with respiratory disease, but more study needed

TUESDAY, May 4 (HealthDay News) -- Treatment with the antibiotic azithromycin doesn't improve the lung function of children and teens with cystic fibrosis, U.S. researchers report.

"A vicious cycle of infection and inflammation causes progressive lung destruction and premature death in patients with cystic fibrosis [CF]. Treatment strategies have therefore included both antimicrobial and anti-inflammatory agents," Dr. Lisa Saiman, of Columbia University in New York City, said in a news release.

Over the past decade, studies have suggested that azithromycin, an antibiotic with both antimicrobial and anti-inflammatory activity, benefits CF patients.

Azithromycin is recommended as therapy for CF patients with chronic infection with the bacteria Pseudomonas aeruginosa, but there has not been enough evidence to support the benefit of azithromycin in other patients with CF, the researchers wrote.

This study, which investigated the possible benefits of expanding the antibiotic therapy to CF patients without the pathogen, included 260 children and teens with CF who were not infected with P. aeruginosa. They were randomly selected to receive either azithromycin or a placebo. After 24 weeks of treatment, there was no difference in lung function between the two groups.

However, researchers found that when compared with the placebo group, the azithromycin group had 50 percent fewer pulmonary exacerbations and 27 percent fewer patients who had to begin new oral antibiotics (other than azithromycin). On average, they also showed a 1.3-pound weight gain and a 0.34-unit increase in body-mass index (important because CF patients often need to gain weight). There were no differences in treatment groups in the use of intravenous or inhaled antibiotics or hospitalizations, Saiman and colleagues added.

They also found that patients who took the antibiotic had less cough and less productive cough than those in the placebo group.

"Further studies of azithromycin are warranted to further investigate its potential use" in CF patients not infected with P. aeruginosa, the researchers concluded.

The study appears in the May 5 issue of the Journal of the American Medical Association.

More information

The U.S. National Library of Medicine has more about cystic fibrosis.



-- Robert Preidt



SOURCE:Journal of the American Medical Association, news release, May 5, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
2. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
3. Rotary Clubs Always Pumped for World Water Day
4. Patient and doctor expectations from joint replacement surgeries not always aligned
5. Its Not Always Women and Children First
6. Liberal Thinking: It, and It Alone, Has Always Been the Force Behind Positive Social Changes in America
7. Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal
8. Top-rated hospitals dont always have superior outcomes
9. Research findings underscore needed action to safeguard lungs of young cancer survivors
10. New technique reduces tobacco smoke damage to lungs in mice
11. Discovery in Lungs May Lead to Treatment for Respiratory Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology: